Abstracts tagged "reactive arthritis and infection"

Abstract Number: 2118 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis
Yushiro Endo¹, Kunihiko Umekita ², Hideki Nakamura ¹, Shoichi Fukui ³, Takahisa Suzuki ⁴, Junya Miyamoto ⁵, Toshimasa Shimizu ¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Tomoki Origuchi ⁶, Akitomo Okada ⁷, Keita Fujikawa ⁸, Akinari Mizokami ⁸, Naoki Matsuoka ⁹, Toshiyuki Aramaki ¹⁰, Yukitaka Ueki ¹⁰, Katsumi Eguchi ¹⁰, Yumi Kariya ², Yayoi Hashiba ¹¹, Toshihiko Hidaka ¹¹, Akihiko Okayama ² and Atsushi Kawakami ¹², ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²University of Miyazaki, Miyazaki, Japan, ³Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Nagasaki, Japan, ⁴Sasebo City General Hospital, Sasebo, Japan, ⁵Nagasaki University Hospital Clinical Research Center, Nagasaki, Japan, ⁶Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁷Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁸JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ¹¹Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: The asymptotic individuals with the human T lymphotropic virus type I (HTLV-I) infection rarely develop adult T cell leukemia/lymphoma (ATL) or HTLV-I–associated myelopathy (HAM).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].